Radiopharm Theranostics (RADX) Stock Explode 200% After Brain Cancer Trial Breakthrough

TLDR

• Radiopharm Theranostics stock jumped 200% after releasing positive interim data from its Phase 2b trial
• The RAD 101 trial showed 92% concordance with MRI in patients with brain metastases
• The company reached 50% enrollment and holds FDA Fast Track Designation for the program
• Management plans to launch a pivotal study by the end of 2026
• The U.S. market opportunity for this treatment is valued at over $500 million

Radiopharm Theranostics stock soared 200% today after the company announced positive results from its ongoing brain cancer trial. The surge came on heavy trading volume as investors reacted to the clinical data.

Radiopharm Theranostics Limited, RADX

The Australian biotechnology company released interim data from its Phase 2b trial of RAD 101. This experimental treatment targets brain metastases, which occur when cancer spreads to the brain from other parts of the body.

The trial met its primary endpoint with a 92% concordance rate compared to MRI scans in evaluable patients. This means the drug successfully identified brain tumors at roughly the same rate as traditional imaging methods.

The study also showed tumor uptake of the radiopharmaceutical compound. This uptake is important because it demonstrates the drug is reaching its intended target in the brain.

Radiopharm Theranostics trades under the ticker RADX in the United States and RAD on the Australian Securities Exchange. The stock had been down 5.12% year-to-date before today’s announcement.

Over the past 12 months, shares had fallen 10.69% prior to the trial results. Today’s 200% gain more than erases those losses for investors who held through the decline.

Trial Progress and FDA Status

The company has now enrolled 50% of patients for the Phase 2b trial. This milestone puts the study at the halfway point toward completion.

RAD 101 has received FDA Fast Track Designation. This special status from regulators is designed to speed up development and review of drugs treating serious conditions with unmet medical needs.

Fast Track Designation provides benefits including more frequent meetings with FDA staff and the possibility of a rolling review. Companies can submit portions of their drug application as they complete them rather than waiting for all studies to finish.

Management stated plans to initiate a pivotal study by the end of 2026. Pivotal trials are the final stage before seeking regulatory approval to sell a drug commercially.

Market Opportunity

Radiopharm Theranostics estimates the U.S. market opportunity for this treatment exceeds $500 million. Brain metastases represent a serious complication for many cancer patients.

The company specializes in radiopharmaceuticals, which are drugs containing radioactive substances. These compounds can both diagnose and treat cancer, an approach called theranostics.

The stock experienced unusual volatility today as traders processed the clinical news. Volume spiked well above typical daily trading levels for the small-cap biotechnology company.

The company has reached 50% enrollment in the Phase 2b trial and holds FDA Fast Track Designation for the RAD 101 program targeting brain metastases.

The post Radiopharm Theranostics (RADX) Stock Explode 200% After Brain Cancer Trial Breakthrough appeared first on Blockonomi.